

ASX ANNOUNCEMENT
23 April 2020

Quarterly Cashflow Report

Bionomics Limited (ASX: BNO, OTCQB: BNOEF), a global, clinical stage biopharmaceutical company, today released its Appendix 4C - Quarterly Cashflow Report. During the quarter:

- the Company completed the sale of its two wholly owned subsidiaries, Neurofit SAS (“Neurofit”) and PC SAS (“Prestwick Chemical”), to Domain Therapeutics (“Domain”). The sale price of €1,790,028.97 was the final amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics’ drug candidates and was assumed by Domain at close.
- Cash balance at 31 March 2020 was \$4.65 million (31 December 2019: \$9.39 million) with net operating cash outflow during the quarter ended 31 March 2020 of \$2.060 million.
- Cash receipts for the quarter ending 31 March 2020 mainly related to receipts from customers totalling \$0.997 million (31 December 2020: \$1.55 million).
- Research & development expenditure decreased to \$0.70 million from \$1.45 million compared with the previous quarter, that is, a decrease of 38%. Details of the research & development activities are summarised in the **Activity Report** below.

Upcoming Milestones:

- The Company is examining its funding sources with an announcement expected not later than Q3 CY2020.
- CEO recruitment is now expected to be completed by Q4 CY2020.
- The Directors will take a reduction of 25% in Directors fees for Q2 CY2020 given the impact of COVID-19 and the current economic uncertainty.
- Bionomics is progressing optimisation of its BNC210 tablets for use in its proposed second Phase 2 Post-Traumatic Stress Disorder (PTSD) trial by conducting testing in an animal study; completion projected in Q2 CY2020.
- Whilst the internal focus and current R&D spend is restricted to CNS programs, Bionomics continues limited activities to maximize the value of its legacy oncology programs BNC101 and BNC105 through external funding of clinical development and divestment/out-licensing.

Activity Report

Bionomics is progressing its lead CNS drug candidate, BNC210, towards a Phase 2 clinical trial in PTSD. During Q1 CY2020 the key activities focussed on developing a new solid dose formulation of BNC210 to improve its exposure in clinical trial subjects.

To achieve this, a contract was signed with Patheon (Oregon, US) at the end of Q4 CY2019 to optimise a tablet formulation of BNC210 and manufacture small batches for evaluation in an animal

pharmacokinetic (PK) study. During Q1 CY2020, the team successfully developed tablet formulations using spray dried dispersion technology and produced *in vitro* characterisation and stability data supporting a promising formulation. At the end of Q1 CY2020, four spray dried dispersion formulations were manufactured into tablets and shipped to Covance (New Jersey, US) for evaluation in a dog PK study. The aim of this study is to compare the PK parameters of these tablets in order to select the best tablet formulation to take into a human multiple dosing PK study projected for Q4 CY2020. PK data from the dog study are anticipated in late Q2 CY2020.

Bionomics is also supporting two Investigator-initiated clinical trials of its oncology drug candidate, BNC105, by providing drug for the trials. Both trials continued to recruit patients during Q1 CY2020. One of these trials, sponsored by the Australasian Gastro-Intestinal Trials Group, completed its recruitment towards the end of Q1 CY2020.

On 3 March 2020 Bionomics completed the sale of its two wholly owned subsidiaries, Neurofit SAS and PC SAS, to Domain Therapeutics ("Domain"). The sale price of €1,790,028.97 was the final amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and was assumed by Domain at close.

For the purpose of Listing Rule 4.7C.3, Directors were paid \$135,000 during the quarter.

AUTHORISED BY THE BOARD

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Ltd.

Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6100
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bionomics Limited

ABN

53 075 582 740

Quarter ended ("current quarter")

31 March 2020

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (9 months) \$A'000 |
|---|------------------------------------|--|
| 1. Cash flows from operating activities | | |
| 1.1 Receipts from customers | 997 | 3,590 |
| 1.2 Payments for | | |
| (a) research and development | (700) | (4,781) |
| (b) product manufacturing and operating costs | - | - |
| (c) advertising and marketing | - | - |
| (d) leased assets | (30) | (135) |
| (e) staff costs | (164) | (751) |
| (f) administration and corporate costs | (921) | (3,471) |
| 1.3 Dividends received (see note 3) | - | - |
| 1.4 Interest received | 12 | 59 |
| 1.5 Interest and other costs of finance paid | (273) | (961) |
| 1.6 Income taxes paid | - | - |
| 1.7 Government grants and tax incentives | - | ,7,288 |
| 1.8 Other | | |
| (a) Rent received | 39 | 118 |
| (b) Payments for contract services | (1,020) | (3,619) |
| 1.9 Net cash from / (used in) operating activities | (2,060) | (2,663) |

| | | | |
|------------|---|--------------|--------------|
| 2. | Cash flows from investing activities | | |
| 2.1 | Payments to acquire: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | - | (7) |
| | (d) investments | - | (52) |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.2 | Proceeds from disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | - |
| | (c) property, plant and equipment | 185 | 233 |
| | (d) investments | - | 550 |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other | | |
| | Net cash outflow from disposal of French operations | | |
| | (i) payments of costs | (94) | (94) |
| | (ii) cash balances disposed of | (801) | (801) |
| 2.6 | Net cash from / (used in) investing activities | (710) | (171) |

| | | | |
|-------------|---|----------------|----------------|
| 3. | Cash flows from financing activities | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | - | - |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | - | - |
| 3.5 | Proceeds from borrowings | - | - |
| 3.6 | Repayment of borrowings | (2,035) | (6,633) |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other (provide details if material) | - | - |
| 3.10 | Net cash from / (used in) financing activities | (2,035) | (6,633) |

| | | | |
|------------|--|--------------|--------------|
| 4. | Net increase / (decrease) in cash and cash equivalents for the period | | |
| 4.1 | Cash and cash equivalents at beginning of period | 9,388 | 13,985 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | (2,060) | (2,663) |
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | (710) | (171) |
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | (2,035) | (6,633) |
| 4.5 | Effect of movement in exchange rates on cash held | 68 | 133 |
| 4.6 | Cash and cash equivalents at end of period | 4,651 | 4,651 |

| | | | |
|------------|---|------------------------------------|-------------------------------------|
| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter \$A'000 | Previous quarter \$A'000 |
| 5.1 | Bank balances | 4,651 | 9,388 |
| 5.2 | Call deposits | - | - |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 4,651 | 9,388 |

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1 (Director Fees)
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

135

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

| Total facility amount at quarter end \$A'000 | Amount drawn at quarter end \$A'000 |
|--|-------------------------------------|
| 12,143 | 12,143 |
| - | - |
| - | - |
| - | - |

7.5 **Unused financing facilities available at quarter end**

-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The loan facility relates to a US dollar borrowing from Silicon Valley Bank and Oxford Finance LLC, effective interest 9.0% and secured by substantially all of the Group's assets, other than intellectual property.

8. Estimated cash available for future operating activities

\$A'000

8.1 Net cash from / (used in) operating activities

(2,060)

8.2 Cash and cash equivalents at quarter end (Item 4.6)

4,651

8.3 Unused finance facilities available at quarter end (Item 7.5)

-

8.4 Total available funding (Item 8.2 + Item 8.3)

4,651

8.5 **Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**

2.26

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 April 2020

By the Board

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.